[Evaluation of the effectiveness and toxicity of pentostam and glucantime in the treatment of cutaneous leishmaniasis].
Sáenz
R E
RE
Paz
H M
HM
Johnson
C M
CM
Narvaez
E
E
de Vásquez
A M
AM
D000328:Adult; D000967:Antimony Sodium Gluconate / Q000009:adverse effects / Q000627:therapeutic use*; D004341:Drug Evaluation; D005260:Female; D005942:Gluconates / Q000627:therapeutic use*; D006801:Humans; D007158:Immunologic Techniques; D007896:Leishmaniasis / Q000188:drug therapy*; D008297:Male; D008536:Meglumine / Q000009:adverse effects / Q000627:therapeutic use*; D000077485:Meglumine Antimoniate; D009942:Organometallic Compounds / Q000009:adverse effects / Q000627:therapeutic use*; D011897:Random Allocation; D013012:Sorbitol / Q000031:analogs & derivatives*
D005942:Gluconates; D009942:Organometallic Compounds; D013012:Sorbitol; D008536:Meglumine; D000077485:Meglumine Antimoniate; D000967:Antimony Sodium Gluconate
Evaluación de la efectividad y toxicidad del pentostam y del glucantime en el tratamiento de la leishmaniasis cutánea.